{{define "nav"}}
The truth I keep coming back to is simple: find value grounded in the fundamental numbers of a company.
My approach is rooted in fundamental analysis using SEC filings (10-K, 10-Q), earnings reports, profitability, liquidity, risk factors, and long-term business sustainability. In low-transparency situations I rely on structured cross-validation across sources.
A pattern I keep seeing is CEOs speaking just close enough to reality to generate a short-term price boost, then moving the goalposts when reality catches up. What companies state in filings and what they communicate to retail or even professional investors can be two very different stories. Guidance only needs to reach far enough into the future to say almost anything.
Reports listed is what i consider still actionable and align with my opinion on the given company at this time. Understand that the infomaion and the time of writing may be dated. The mispricing of the thesis remain valuable.
The company only owns btc by issuing debt and preferred stock offering.
The company is expensive btc at its best and ponzi scheme at its worst.
The product sales of wieght loss drugs are highclass, pipeline is undervalued.
Pipeline and wegovy pil is not reconsiced correctly as high focus on expireation of current sold product. high pisimistic view of pipeline.
year to date performance has its risked and luck based issues. hard to say if these numbers will continue year by year.
mostly long trades on NOVO, MEARSK, ORTSED and VWS with a low wieght of puts on RGTI